European urology

(ISSN: 0302-2838, 1873-7560)

European urology's Latest Table of Contents

2017 - 72 (3)

  • Reply from Authors re: Mikkel Fode, Jens Sønksen. Towards a Greater Understanding of Underactive Bladder. Eur Urol 2017;72:408-9. 
  • Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60: Methodological Issues to Avoid Misinterpretation. 
  • Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. 
  • Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer. 
  • Reply to Lorenzo Marconi, Steven MacLennan, Thomas B.L. Lam, et al's Letter to the Editor re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017;71:606-17. 
  • Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation. 
  • Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1-3. 
  • Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017;71:606-17. 
  • Re: 10-Year Outcomes After Monitoring, Surgery or Radiotherapy for Localized Prostate Cancer. 
  • Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement. 
  • Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. 
  • Improving Quality in Renal Cell Carcinoma Care: Bridging the Gap Between Measurement and Meaning. 
  • Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders? 
  • Corrigendum re: "Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial" [Eur Urol 2015;68:216-25]. 
  • The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening. 
  • Re: Lower Urinary Tract Symptoms and Incident Falls in Community Dwelling Older Men: The Concord Health and Ageing in Men Project. 
  • Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer. 
  • The Impact of Quality Variations on Patients Undergoing Surgery for Renal Cell Carcinoma: A National Cancer Database Study. 
  • Re: Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. 
  • Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. 
  • Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models. 
  • Corrigendum re: "Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group" [Eur Urol 2017;71:723-6]. 
  • Towards a Greater Understanding of Underactive Bladder. 
  • RECISTing the Temptation to Prematurely Stop Nivolumab. 
  • Seeking the Molecular Truth in Bladder Cancer: Biology=Genome×(Transcriptome)2. 
  • Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. 
  • Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. 
  • Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. 
  • Qualitative Exploration of the Patient Experience of Underactive Bladder. 
  • Better Persistence Rates with Mirabegron: Questions Raised. 
  • Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer. 
  • Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. 
  • KIUrologyX: Urology As You Like It-A Massive Open Online Course for Medical Students, Professionals, Patients, and Laypeople Alike. 
  • Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. 
  • Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14. 
  • Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14. 
  • Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. 
  • Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. 
  • Salvage Surgery for Nodal Recurrence of Prostate Cancer: Might the Robotic Approach Render an Experimental Procedure More Acceptable? 
  • Partial Prostatectomy for Anterior Cancer: Short-term Oncologic and Functional Outcomes. 
  • Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer. 
  • Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance. 
  • Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance.